Cat. No.: HY-15186

Ipatasertib

(Synonyms: GDC-0068; RG7440)

63 Cited Publications

Avis client

Based on 63 publication(s) in Google Scholar

Ipatasertib (GDC-0068) is an orally active, highly selective and ATP-competitive pan-Akt inhibitor with IC₅₀ values of 5, 18, 8 nM for Akt1/2/3, respectively. Ipatasertib synchronously activates FoxO3a and NF-κB through inhibition of Akt leading to p53-independent activation of PUMA. Ipatasertib also induces apoptosis in cancer cells and inhibits tumor growth in xenograft mouse models.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.74%
CAS No.: 1001264-89-6
Formule: C₂₄H₃₂ClN₅O₂
Masse moléculaire:458.00

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Ipatasertib Chemical Structure

CAS No.: 1001264-89-6

Size

Prix

Stock

Quantité

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Obtenir un devis Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Obtenir un devis Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (63)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Bioz

Activité biologique

Description

IC₅₀ & Target^[2]

Akt1

5 nM (IC₅₀)

Akt3

8 nM (IC₅₀)

Akt2

18 nM (IC₅₀)

PKA

3100 nM (IC₅₀)

Voir tous les produits spécifiques à Isoform Akt :

Cellular Effect

Cell Line	Type	Value	Description	References
AN3-CA	EC₅₀	925 nM Compound: Ipatasertib	Antiproliferative activity against human AN3-CA cells assessed as reduction in cell viability incubated for 5 days by celltiter-glo assay Antiproliferative activity against human AN3-CA cells assessed as reduction in cell viability incubated for 5 days by celltiter-glo assay	[PMID: 30996949]
BT-474	EC₅₀	2371 nM Compound: Ipatasertib	Antiproliferative activity against human BT-474 cells assessed as reduction in cell viability incubated for 5 days by celltiter-glo assay Antiproliferative activity against human BT-474 cells assessed as reduction in cell viability incubated for 5 days by celltiter-glo assay	[PMID: 30996949]
BT-474	GI₅₀	0.3 μM Compound: GDC-0068	Antiproliferative activity against human BT-474 cells assessed as growth inhibition incubated for 5 days by IncuCyte live-cell imaging analysis Antiproliferative activity against human BT-474 cells assessed as growth inhibition incubated for 5 days by IncuCyte live-cell imaging analysis	[PMID: 34855399]
C-33-A	IC₅₀	725.97 nM Compound: GDC-0068	Antiproliferative activity against human C-33-A habouring PTEN deletion mutant assessed as reduction in cell viability incubated for 72 hrs by Cell Titer Glo luminescent assay Antiproliferative activity against human C-33-A habouring PTEN deletion mutant assessed as reduction in cell viability incubated for 72 hrs by Cell Titer Glo luminescent assay	[PMID: 35679512]
CAL-51	IC₅₀	265.2 nM Compound: GDC-0068	Antiproliferative activity against human CAL-51 habouring PTEN deletion and PIK3CA mutation/amplication assessed as reduction in cell viability incubated for 72 hrs by Cell Titer Glo luminescent assay Antiproliferative activity against human CAL-51 habouring PTEN deletion and PIK3CA mutation/amplication assessed as reduction in cell viability incubated for 72 hrs by Cell Titer Glo luminescent assay	[PMID: 35679512]
Hep 3B2	IC₅₀	389 μM Compound: GDC-0068	Cytotoxicity against human Hep3B cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human Hep3B cells assessed as reduction in cell viability by MTT assay	[PMID: 32007668]
HepG2	IC₅₀	0.268 μM Compound: GDC-0068	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay	[PMID: 32007668]
Huh-7	IC₅₀	0.167 μM Compound: GDC-0068	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability by MTT assay	[PMID: 32007668]
KU-19-19	EC₅₀	24037 nM Compound: Ipatasertib	Antiproliferative activity against human KU-19-19 cells assessed as reduction in cell viability incubated for 5 days by celltiter-glo assay Antiproliferative activity against human KU-19-19 cells assessed as reduction in cell viability incubated for 5 days by celltiter-glo assay	[PMID: 30996949]
LNCaP	IC₅₀	157 nM Compound: 28, GDC-0068	Inhibition of Akt1 in human LNCAP cells assessed as phosphorylation of PRAS40 at Thr246 after 1.5 hrs Inhibition of Akt1 in human LNCAP cells assessed as phosphorylation of PRAS40 at Thr246 after 1.5 hrs	[PMID: 22934575]
LNCaP	IC₅₀	95 nM Compound: 28, GDC-0068	Cytotoxicity against human LNCAP cells assessed as reduction of resazurin to resorufin after 72 hrs Cytotoxicity against human LNCAP cells assessed as reduction of resazurin to resorufin after 72 hrs	[PMID: 22934575]
MCF7	EC₅₀	5036 nM Compound: Ipatasertib	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 5 days by celltiter-glo assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 5 days by celltiter-glo assay	[PMID: 30996949]
MCF7	IC₅₀	1 μM Compound: 28, GDC-0068	Cytotoxicity against human MCF7 cells overexpressing Her2 assessed as decrease in cell viability after 96 hrs by CellTitre-Glo assay Cytotoxicity against human MCF7 cells overexpressing Her2 assessed as decrease in cell viability after 96 hrs by CellTitre-Glo assay	[PMID: 22934575]
MDA-MB-468	GI₅₀	3.7 μM Compound: GDC-0068	Antiproliferative activity against human MDA-MB-468 cells assessed as growth inhibition incubated for 5 days by IncuCyte live-cell imaging analysis Antiproliferative activity against human MDA-MB-468 cells assessed as growth inhibition incubated for 5 days by IncuCyte live-cell imaging analysis	[PMID: 34855399]
NCI-H1975	IC₅₀	>20 μM Compound: 2; GDC-0068	Antiproliferative activity against human osimertinib resistant NCI-H1975 cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay Antiproliferative activity against human osimertinib resistant NCI-H1975 cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay	[PMID: 36173763]
PC-3	GI₅₀	7.6 μM Compound: GDC-0068	Antiproliferative activity against human PC-3 cells assessed as growth inhibition incubated for 5 days by IncuCyte live-cell imaging analysis Antiproliferative activity against human PC-3 cells assessed as growth inhibition incubated for 5 days by IncuCyte live-cell imaging analysis	[PMID: 34855399]
PC-3	IC₅₀	1 μM Compound: 28, GDC-0068	Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 96 hrs by CellTitre-Glo assay Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 96 hrs by CellTitre-Glo assay	[PMID: 22934575]
PC-3	IC₅₀	3544.33 nM Compound: GDC-0068	Antiproliferative activity against human PC-3 habouring PTEN deletion and PIK3CA mutation/amplication assessed as reduction in cell viability incubated for 72 hrs by Cell Titer Glo luminescent assay Antiproliferative activity against human PC-3 habouring PTEN deletion and PIK3CA mutation/amplication assessed as reduction in cell viability incubated for 72 hrs by Cell Titer Glo luminescent assay	[PMID: 35679512]
RL95-2	IC₅₀	331.07 nM Compound: GDC-0068	Antiproliferative activity against human RL95-2 habouring PTEN deletion mutant assessed as reduction in cell viability incubated for 72 hrs by Cell Titer Glo luminescent assay Antiproliferative activity against human RL95-2 habouring PTEN deletion mutant assessed as reduction in cell viability incubated for 72 hrs by Cell Titer Glo luminescent assay	[PMID: 35679512]
SMMC-7721	IC₅₀	0.661 μM Compound: GDC-0068	Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability by MTT assay	[PMID: 32007668]
T47D	EC₅₀	443 nM Compound: Ipatasertib	Antiproliferative activity against human T47D cells assessed as reduction in cell viability incubated for 5 days by celltiter-glo assay Antiproliferative activity against human T47D cells assessed as reduction in cell viability incubated for 5 days by celltiter-glo assay	[PMID: 30996949]
T47D	IC₅₀	327.77 nM Compound: GDC-0068	Antiproliferative activity against human T47D habouring PIK3CA mutation/amplication assessed as reduction in cell viability incubated for 72 hrs by Cell Titer Glo luminescent assay Antiproliferative activity against human T47D habouring PIK3CA mutation/amplication assessed as reduction in cell viability incubated for 72 hrs by Cell Titer Glo luminescent assay	[PMID: 35679512]
TOV21G	IC₅₀	715.2 nM Compound: GDC-0068	Antiproliferative activity against human TOV-21G habouring PTEN deletion and PIK3CA mutation/amplication assessed as reduction in cell viability incubated for 72 hrs by Cell Titer Glo luminescent assay Antiproliferative activity against human TOV-21G habouring PTEN deletion and PIK3CA mutation/amplication assessed as reduction in cell viability incubated for 72 hrs by Cell Titer Glo luminescent assay	[PMID: 35679512]
ZR-75-1	EC₅₀	219 nM Compound: Ipatasertib	Antiproliferative activity against human ZR-75-1 cells assessed as reduction in cell viability incubated for 5 days by celltiter-glo assay Antiproliferative activity against human ZR-75-1 cells assessed as reduction in cell viability incubated for 5 days by celltiter-glo assay	[PMID: 30996949]
ZR-75-1	IC₅₀	1316 nM Compound: GDC-0068	Antiproliferative activity against human ZR-75-1 habouring PTEN deletion mutant assessed as reduction in cell viability incubated for 72 hrs by Cell Titer Glo luminescent assay Antiproliferative activity against human ZR-75-1 habouring PTEN deletion mutant assessed as reduction in cell viability incubated for 72 hrs by Cell Titer Glo luminescent assay	[PMID: 35679512]

In Vitro

Ipatasertib (10 µM; 12, 24 h) suppresses colon cancer cell proliferation by p53 irrespectively activating PUMA in vitro^[1].
Ipatasertib (1, 5, 10, 20 μM; 24 h/10 μM; 3, 6, 12, 24 h) up-regulates the expression level of PUMA in a concentration and time dependent manner in HCT116 cells^[1].
Ipatasertib increases the mRNA level of PUMA in HCT116 WT, p53^−/−, and DLD1 (p53 mutant) cells^[1].
Ipatasertib (10 µM; 24 h) induces apoptosis through PUMA/Bax pathway in HCT116 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

HCT116 WT, p53^−/−, and DLD1 (p53 mutant) cells
Concentration:

10 µM
Incubation Time:

12, 24 h
Result:

Decreased all the three cell lines viability.

Apoptosis Analysis^[1]

Cell Line:

HCT116 cells
Concentration:

10 µM
Incubation Time:

24 h
Result:

Induced apoptosis through PUMA/Bax pathway.

Western Blot Analysis^[1]

Cell Line:

HCT116 cells
Concentration:

1, 5, 10, 20 μM for 24 h/10 μM for 3, 6, 12, 24 h
Incubation Time:

24 h; 3, 6, 12, 24 h
Result:

Increased the level of PUMA in a concentration and time dependent manner.

In Vivo

Ipatasertib (30 mg/kg; p.o.; single daily for 15 consecutive days) exhibits PUMA-dependent antitumor activity in HCT116 WT and PUMA^−/− cells xenograft nude mice model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

HCT116 WT and PUMA^−/− cells xenograft nude mice model^[1].
Dosage:

30 mg/kg
Administration:

Oral gavage; single daily for 15 consecutive days.
Result:

Inhibited growth of tumors in a PUMA-dependent manner.

Chemical Information

CAS No. 1001264-89-6
Appearance Solid
Masse moléculaire 458.00
Formule C₂₄H₃₂ClN₅O₂
Color White to light yellow
SMILES

ClC1=CC=C([C@@H](CNC(C)C)C(N2CCN(C3=C([C@H](C)C[C@H]4O)C4=NC=N3)CC2)=O)C=C1
Synonyms

GDC-0068; RG7440
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (63)

All WBCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Cell Metab

Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape. [Abstract]

2021 Nov 2;33(11):2247-2259.e6. PMID: 34731655
Blood

DLBCL associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemo-resistance. [Abstract]

2023 Sep 14;142(11):973-988. PMID: 37235754
Nat Cell Biol

Chromosome mis-segregation triggers cell cycle arrest through a mechanosensitive nuclear envelope checkpoint. [Abstract]

2025 Jan;27(1):73-86. PMID: 39779939
Cancer Res

Genomic Alterations in PIK3CA-Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3Kα Inhibitors. [Abstract]

2021 May 1;81(9):2470-2480. PMID: 33685991
Mol Cell

DNA Damage Promotes TMPRSS2-ERG Oncoprotein Destruction and Prostate Cancer Suppression via Signaling Converged by GSK3β and WEE1. [Abstract]

2020 Sep 17;79(6):1008-1023.e4. PMID: 32871104
Mol Cell

Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression. [Abstract]

2019 Jan 3;73(1):22-35.e6. PMID: 30527665
Nat Commun

Attenuated growth factor signaling during cell death initiation sensitizes membranes towards peroxidation. [Abstract]

2025 Feb 25;16(1):1774. PMID: 40000627

Ipatasertib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 25;16(1):1774. [Abstract]

Viable cell numbers and PUFA-PC ratio after treatment with LY294002 (iPI3K, 10 µM), picropodophyllin (iRTK, 10 µM), ipatasertib (iAkt, 10 µM), or fatostatin (iSREBP1, 20 µM) for 48 h.
Nat Commun

An actin bracket-induced elastoplastic transition determines epithelial folding irreversibility. [Abstract]

2024 Dec 12;15(1):10476. PMID: 39668169
Sci Transl Med

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]

2018 Jul 18;10(450):eaaq1093. PMID: 30021885
Nat Chem Biol

Pharmacodynamics of Akt drugs revealed by a kinase-modulated bioluminescent indicator. [Abstract]

2025 Aug;21(8):1194-1204. PMID: 39934397
Biomaterials

FAK-p38 signaling serves as a potential target for reverting matrix stiffness-modulated liver sinusoidal endothelial cell defenestration. [Abstract]

2024 Mar:305:122462. PMID: 38171118
Sci Adv

BRD9 functions as a methylarginine reader to regulate AKT-EZH2 signaling. [Abstract]

2025 Apr 25;11(17):eads6385. PMID: 40279411
Sci Adv

Breast tumors interfere with endothelial TRAIL at the premetastatic niche to promote cancer cell seeding. [Abstract]

2023 Mar 22;9(12):eadd5028. PMID: 36947620
Int J Biol Sci

High-dose Ascorbate Exhibits Anti-proliferative and Anti-invasive Effects Dependent on PTEN/AKT/mTOR Pathway in Endometrial Cancer in vitro and in vivo. [Abstract]

2025 Jan 27;21(4):1545-1565. PMID: 39990670
EMBO Mol Med

PlexinD1 is a driver and a therapeutic target in advanced prostate cancer. [Abstract]

2025 Feb;17(2):336-364. PMID: 39748059
Haematologica

Multilevel defects in the hematopoietic niche in essential thrombocythemia. [Abstract]

2020 Mar;105(3):661-673. PMID: 31289202
Oncogene

Identification of RAPGEF3 as the therapeutic vulnerability of basal-subtype lung squamous cell carcinoma. [Abstract]

2025 Sep;44(34):3142-3148. PMID: 40781157
Cell Rep

An acetyl-histone vulnerability in PI3K/AKT inhibition-resistant cancers is targetable by both BET and HDAC inhibitors. [Abstract]

2021 Feb 16;34(7):108744. PMID: 33596421
Br J Cancer

Inhibition of YB-1 phosphorylation enhances cisplatin activity and disrupts cell division in pleural mesothelioma. [Abstract]

2025 Sep 4. PMID: 40908296
Elife

Cohesin mutations are synthetic lethal with stimulation of WNT signaling. [Abstract]

2020 Dec 7;9:e61405. PMID: 33284104
Oncoimmunology

Ex vivo AKT-inhibition facilitates generation of polyfunctional stem cell memory-like CD8+ T cells for adoptive immunotherapy. [Abstract]

2018 Aug 6;7(10):e1488565. PMID: 30288356
EMBO Rep

IGF1R regulates retrograde axonal transport of signalling endosomes in motor neurons. [Abstract]

2020 Mar 4;21(3):e49129. PMID: 32030864
Biochem Pharmacol

20(S)-ginsenoside Rg3 promotes myoblast differentiation and protects against myotube atrophy via regulation of the Akt/mTOR/FoxO3 pathway. [Abstract]

2020 Oct;180:114145. PMID: 32653593

Ipatasertib purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2020 Oct;180:114145. [Abstract]

C2C12 myoblasts were pre-incubated with 2.5 μM GDC-0068 for 30 min then treated with 0.2 μM S-Rg3. After incubation with S-Rg3 for 72 h and 24 h, Western blotting is used to detect levels of Myf5 and myogenin in C2C12 myoblasts after incubation of cells with S-Rg3 for 120 h. GDC-0068 inhibits S-Rg3-activated phosphorylation of Akt and mTOR in C2C12 myoblasts.
Mol Cancer Ther

AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer. [Abstract]

2024 Oct 1;23(10):1404-1417. PMID: 38894678
J Mol Liq

2026 May 23;457:129686.
Life Sci

Early-senescent bone marrow mesenchymal stem cells promote C2C12 cell myogenic differentiation by preventing the nuclear translocation of FOXO3. [Abstract]

2021 Jul 15:277:119520. PMID: 33887345
Cancer Immunol Immunother

Cell composition and expansion strategy can reduce the beneficial effect of AKT-inhibition on functionality of CD8+ T cells. [Abstract]

2020 Nov;69(11):2259-2273. PMID: 32504246
Life Sci

Low SCRIB expression in fibroblasts promotes invasion of lung cancer cells. [Abstract]

2020 Sep 1;256:117955. PMID: 32534038
Int J Cancer

Effects of Metformin on the virus/host cell crosstalk in human papillomavirus-positive cancer cells. [Abstract]

2021 Sep 1;149(5):1137-1149. PMID: 33844847
Mol Oncol

Olaparib synergy screen reveals Exemestane induces replication stress in triple-negative breast cancer. [Abstract]

2025 Jul 13. PMID: 40652528
Mol Oncol

Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis. [Abstract]

2024 Mar;18(3):726-742. PMID: 38225213
Cancers (Basel)

Oleic Acid Exhibits Anti-Proliferative and Anti-Invasive Activities via the PTEN/AKT/mTOR Pathway in Endometrial Cancer. [Abstract]

2023 Nov 14;15(22):5407. PMID: 38001668
Skelet Muscle

MiR-1290 promotes myoblast differentiation and protects against myotube atrophy via Akt/p70/FoxO3 pathway regulation. [Abstract]

2021 Mar 15;11(1):6. PMID: 33722298

Ipatasertib purchased from MedChemExpress. Usage Cited in: Skelet Muscle. 2021 Mar 15;11(1):6. [Abstract]

The western blot analysis and quantification of phosphorylated and all forms of AKT and P70, MyoG, and MyoD, after transfecting miR-1290/miR-NC with or without GDC0068. GDC-0068 inhibits miR-1290-activated phosphorylation of AKT and P70 in C2C12 myoblasts.
Sci Rep

Dendrobium officinale Kimura & Migo polysaccharide ameliorates skin photoaging by promoting angiogenesis. [Abstract]

2025 Aug 17;15(1):30048. PMID: 40820014
Oncol Rep

Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues. [Abstract]

2018 Aug;40(2):635-646. PMID: 29917168
Front Oncol

Zotatifin, an eIF4A-Selective Inhibitor, Blocks Tumor Growth in Receptor Tyrosine Kinase Driven Tumors. [Abstract]

2021 Nov 24:11:766298. PMID: 34900714

Ipatasertib purchased from MedChemExpress. Usage Cited in: Front Oncol. 2021 Nov 24:11:766298. [Abstract]

Ipatasertib (0.625, 1.25, 5 µM; 24 h) increases the phosphorylation of AKT in MFM-223 FGFR2amp cells.
Ren Fail

A multi-omics landscape of programmed cell death in acetaminophen-induced acute kidney injury. [Abstract]

2025 Dec;47(1):2580064. PMID: 41249093
Int J Hyperthermia

Impacts of hyperthermic chemotherapeutic agent on cytotoxicity, chemoresistance-related proteins and PD-L1 expression in human gastric cancer cells. [Abstract]

2024 Feb 13;41(1):2310017. PMID: 38350654
J Cell Biochem

AKT1 Promotes Tumorigenesis and Metastasis by Directly Phosphorylating Hexokinases. [Abstract]

2024 Aug;125(8):e30613. PMID: 38860522
Oncotargets Ther

Inhibition of PI3K-AKT Signaling Blocks PGE2-Induced COX-2 Expression in Lung Adenocarcinoma. [Abstract]

2020 Aug 18;13:8197-8208. PMID: 32904445
Steroids

Kobochromone A, a polyphenol in Carex kobomugi, suppresses androgen signaling induced by 11-oxygenated androgens and enhances the efficacy of AKT inhibitors in triple-negative breast cancer cells. [Abstract]

2025 Sep 25:223:109692. PMID: 41015102
Biochem Biophys Res Commun

Loss of DNA replication fork protection by TIMELESS degradation supports oncogene-induced senescence. [Abstract]

2025 Jun 12:776:152203. PMID: 40517672
Biomed Chromatogr

A validated LC-MS/MS method for the quantification of capivasertib in dog plasma: Application to its pharmacokinetics study. [Abstract]

2020 Oct;34(10):e4920. PMID: 32537750
Biomed Chromatogr

Pharmacokinetics and bioavailability of ipatasertib in dog plasma using LC/MS/MS. [Abstract]

2020 Oct;34(10):e4923. PMID: 32558944
Res Sq

ERG function in prostate cells is regulated by distinct positive feedback loops depending on AKT signaling status. [Abstract]

2026 Jun 15:rs.3.rs-9941989. PMID: 42370241
bioRxiv

2026 Apr 9.
Res Sq

2026 Jan 15.
Technical University of Dresden

2025.
Universite du Quebec

2025.
Preprints

2025 Nov 18.
bioRxiv

AI-assisted Drug Re-purposing for Human Liver Fibrosis. [Abstract]

2025 May 4:2025.04.29.651320. PMID: 40654780
bioRxiv

2025 March 20.
bioRxiv

2024 August 26.
Research Square Preprint

2024 Nov 26.
bioRxiv

2024 August 18.
bioRxiv

2024 September 07.
bioRxiv

2024 Jan 16.
SSRN

2023 Jun 20.
Patent

US20220313694A1.
Cold Spring Harb Mol Case Stud

Functional impact and targetability of PI3KCA, GNAS, and PTEN mutations in a spindle cell rhabdomyosarcoma with MYOD1 L122R mutation. [Abstract]

2022 Jan 10;8(1):a006140. PMID: 35012940
Oxid Med Cell Longev

Exosomes Released from CaSR-Stimulated PMNs Reduce Ischaemia/Reperfusion Injury. [Abstract]

2021 Jan 12;2021:3010548. PMID: 33505580
Radboud University Nijmegen

2019 Oct.
Oncotarget

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML. [Abstract]

2016 May 17;7(20):29131-42. PMID: 27074558

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (218.34 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 3.57 mg/mL (7.79 mM; ultrasonic and warming and heat to 60°C)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1834 mL

10.9170 mL

21.8341 mL

5 mM

0.4367 mL

2.1834 mL

4.3668 mL

10 mM

0.2183 mL

1.0917 mL

2.1834 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 5 mg/mL (10.92 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 5 mg/mL (10.92 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 5 mg/mL (10.92 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (281 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Sun L, et al. Ipatasertib, a novel Akt inhibitor, induces transcription factor FoxO3a and NF-κB directly regulates PUMA-dependent apoptosis. Cell Death Dis. 2018 Sep 5;9(9):911. [Content Brief]

[2]. Blake JF, et al. Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors. J Med Chem. 2012 Sep 27;55(18):8110-27. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	2.1834 mL	10.9170 mL	21.8341 mL	54.5852 mL
H₂O / DMSO	5 mM	0.4367 mL	2.1834 mL	4.3668 mL	10.9170 mL
DMSO	10 mM	0.2183 mL	1.0917 mL	2.1834 mL	5.4585 mL
	15 mM	0.1456 mL	0.7278 mL	1.4556 mL	3.6390 mL
	20 mM	0.1092 mL	0.5459 mL	1.0917 mL	2.7293 mL
	25 mM	0.0873 mL	0.4367 mL	0.8734 mL	2.1834 mL
	30 mM	0.0728 mL	0.3639 mL	0.7278 mL	1.8195 mL
	40 mM	0.0546 mL	0.2729 mL	0.5459 mL	1.3646 mL
	50 mM	0.0437 mL	0.2183 mL	0.4367 mL	1.0917 mL
	60 mM	0.0364 mL	0.1820 mL	0.3639 mL	0.9098 mL
	80 mM	0.0273 mL	0.1365 mL	0.2729 mL	0.6823 mL
	100 mM	0.0218 mL	0.1092 mL	0.2183 mL	0.5459 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Ipatasertib

63 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Ipatasertib

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Targeted Diversity Library

Anti-Liver Cancer Compound Library

Rare Diseases Drug Library

Anti-Colorectal Cancer Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

Kinase Inhibitor Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Ipatasertib

Voir tous les produits spécifiques à Isoform Akt

Activité biologique

Chemical Information

Publications (63)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Ipatasertib Related Classifications

Cat. No.: HY-15186